Duopharma Biotech Bhd

Duopharma Biotech Bhd EBIT per Employee

The EBIT per Employee of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 3, 2026 is 66,568.12 MYR. In the previous year, EBIT per Employee was 52,059.52 MYR — a change of 27.87% (higher).

EBIT per Employee

66,568.12MYR

YoY

27.87%

Last updated:

EBIT per Employee of Duopharma Biotech Bhd is 2024 66,568.12 MYR. EBIT per Employee of Duopharma Biotech Bhd was 2023 52,059.52 MYR. It decreases by 27.87% higher compared to the previous year.

The Duopharma Biotech Bhd EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2017
35,927.91 MYR
Jan 1, 2018
43,177.25 MYR
Jan 1, 2019
51,080.03 MYR
Jan 1, 2020
54,137.57 MYR
Jan 1, 2021
58,703.04 MYR
Jan 1, 2022
61,448.41 MYR
Jan 1, 2023
52,059.52 MYR
Jan 1, 2024
66,568.12 MYR
The Duopharma Biotech Bhd EBIT per Employee history
YEAREBIT per EmployeeYoY
66,568.12MYR+27.87%
52,059.52MYR-15.28%
61,448.41MYR+4.68%
58,703.04MYR+8.43%
54,137.57MYR+5.99%
51,080.03MYR+18.30%
43,177.25MYR+20.18%
35,927.91MYR+65.64%
21,689.81MYR-34.65%
33,191.14MYR+7.29%
30,935.19MYR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

EBIT per Employee of Duopharma Biotech Bhd is 66,568.12 MYR in 2024.

EBIT per Employee of Duopharma Biotech Bhd changed from 52,059.52 MYR to 66,568.12 MYR, representing a 27.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's MYR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Duopharma Biotech Bhd historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd